Multidrug-resistant tuberculosis (MDR-TB) is a cause of increasing concern. This study investigated first-line anti-TB drug resistance in Mycobacterium tuberculosis strains submitted to the Tuberculosis Reference Center in Córdoba (Spain) between 2001 and 2015. A total of 1,207 cultures were tested against first-line drugs using the BACTEC MGIT 960 system. Resistance to first-line drugs was detected in 207 strains (17.2%), the greatest resistance being found in INH (5.3%) followed by streptomycin (3%), pyrazinamide (2.2%), rifampicin (1%), and ethambutol (0.2%). A total of 1.9% of strains were MDR-TB. Six strains displayed resistance to four drugs, and three strains to five drugs. In view of resistance observed, careful surveillance of drug resistance is recommended.
Get full access to this article
View all access options for this article.
References
1.
World Health Organization. 2017. Global Tuberculosis Report 2017. WHO, Geneva.
2.
YoumansG.P., WillistonE.H., FeldmanW.H., and HinshawH.C.. 1946. Increase in resistance of tubercle bacilli to streptomycin; a preliminary report. Proc. Staff Meet. Mayo Clin., 21:126–127.
3.
JindaniA.1976. Short-course (6-month) treatment of pulmonary tuberculosis (Second East African/British Medical Research Council Study). Bull. Int. Union Tuberc., 51:53–56.
4.
PearsonM.L., JorepJ.A., and FriedenT.R.. 1970. Nosocomial transmission of multidrug-resistant tuberculosis. N. Engl. J. Med., 283:191–196.
5.
EdlinB., TokarsJ.L., and CriecoH.. 1992. An outbreak of multidrug-resistant tuberculosis among hospitalised patients with the acquired immunodeficiency syndrome. N. Engl. J. Med., 326:514–1521.
6.
FischlM.A., UttamchardamiR.B., and DaikosG.L.. 1992. An ourbreak of TB caused by multidrug–resistant tubercle bacilli among patients with HIV infection. Ann. Intern. Med., 117:177–183.
7.
CasalM, VaqueroM., RinderH., TortoliE., GrossetJ., Rusch-GerdesS., GutiérrezJ.B., and JarlierV.A.. 2005. Case–control study for multidrug-resistant tuberculosis risk factors in four European countries. Microb. Drug Resist., 11:61–65.
8.
JacobsR.F.1994. Multiple DR tuberculosis. Clin. Infect. Dis., 19:1–10.
9.
ReisnerB.S., GatsonA.M., and WoodsG.L.. 1994. Use of Gen-Probe AccuProbes to identify Mycobacterium avium complex, Mycobacterium tuberculosis complex, Mycobacterium kansasii, and Mycobacterium gordonae directly from BACTEC TB broth cultures. J. Clin. Microbiol., 32:2995–2998.
10.
RuizP., ZeroloF.J., and CasalM.. 2000. Comparison of susceptibility testing of Mycobacterium tuberculosis using the ESP culture system II with that using the BACTEC method. J. Clin. Microbiol., 38:4663–4664.
11.
RichterE., Rüsch-GerdesS., and HillemannD.. 2006. Evaluation of the GenoType mycobacterium assay for identification of mycobacterial species from cultures. J. Clin. Microbiol., 44:1769–1775.
12.
Rüsch-GerdesS., DomehlC., NardiG., GismondoM.R., WelscherH.-M., and PfyfferG.E.. 1999. Multicenter evaluation of the Mycobacterial growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs. J. Clin. Microbiol., 37:45–48.
13.
AznarE., DomingoD., AbanadesE., García-PeñuelaE., and López-BreaM.. 2005. Resistencia en Mycobacteriumtuberculosis durante un periodo de cuatro años en un hospital de Madrid. Rev. Esp. Quimioterapia., 18:222–225.
14.
Aragó GalindoM., Belda MiraA., Albert ContellA., Serra SanchisB., Amorós QuilesI., Prat FornellsJ., Escorns TrullenqueR., and GonzálezC.. 2006. Mycobacterium tuberculosis resistance in the hospital area of Sagunto from 1999 to 2004. [In Spanish]. Rev. Clin. Esp., 206:376–381.
15.
Remacha EsterasM.A., Parra ParraI., Esteban MartínA. and Blanco MercadéM.D.. 2003. Mycobacterium tuberculosis resistance in a hospital in Leon. [In Spanish]. Rev. Esp. Quimioterap., 16:455–456.
16.
ÁlvarezD., ValleJ.M., MartinoM.V., GordoP., CarreiraJ., and ValdésL.. 1994. Study of the primary resistance to antiberculosis drugs in Galicia. [In Spanish]. Arch. Bronconeumol., 30:297–300.
17.
Alberte -CastiñeirasA., Campos-BuenoA., Lopez-UrrutiaL., Alvarez-AlonsoE., MegíasG., Ojeda-FernandezE., Lopez-MedranoR., Iglesias GarcíaJ., García-CarbajosaS., and Pérez-PascualP.. 2010. Mycobacterium tuberculosis drug resistance in Castilla and Leon Community, 2001–2005: third multicentric study. [In Spanish]. Enferm. Infecc. Microbiol. Clin., 28:706–709.
18.
CasalM., GutiérrezJ.B., and RuizP.. 2000. Current status of multiple drug resistance in tuberculosis. [In Spanish]. Rev. Esp. Quimioterap., 13:167–170.
19.
IdigorasP., ValienteA., IglesiasL., PiñeiroL., and Pérez-TralleroE.. 2002. Low level of drug resistance in Mycobacterium tuberculosis strains isolated in Gipuzkoa (1993–2001). [In Spanish]. Enferm. Infecc. Microbiol. Clin, 20:187–188.
20.
JiménezM.S., and CasalM.. 2008. Drug resistance situation to Mycobacterium tuberculosis in Spain. [In Spanish]. Rev. Esp. Quimioterapia., 21:22–25.
21.
Marín RoyoM., González MoránF., Moreno MuñozR., Pardo SerranoF., Prada AlfaroP., Arnedo PenaA., and Aguar BenitoM.C.. 2000. Evolution of Mycobacterium tuberculosis resistance in Castellón province. Years 1992–1998. [In Spanish]. Arch. Bronconeumol., 36:551–556.
22.
Martín-CasabonaN., AlcaideF., CollP., GonzálezJ., ManterolaJ.M., SalvadóM., and CaylàJ.A.. 2000. Drug resistance of Mycobacterium tuberculosis. Multicentric study in the Barcelona area. [In Spanish]. Med. Clin., 115:493–498.
23.
Ruiz LópezF.J., Zarauz GarcíaJ.M., Ortiz RomeroM.M., Valero MartinezJ.R., Peñalver MelladoC., Sánchez GascónF., and Lorenzo CruzM.. 2006. Tuberculosis in Lorca region: adapt or resist. [In Spanish]. An. Med. Interna., 23:321–325.
24.
Sanz BarberoB., and Blasco HernándezT..2007. Current status of Mycobacterium tuberculosis resistances in the immigrant population of Madrid community. [In Spanish]. Arch. Bronconeomol., 43:324–333.
25.
Tirado BalaguerM.D., Moreno MuñozR., Marín RoyoM., González MoránF., Pardo SerranoF., García del Busto RemónA., and Prada AlfaroP.. 2006. Impact of immigration on Mycobacterium tuberculosis resistance in Castellón province: 1995–2003. [In Spanish]. Med. Clin., 126:761–764.
26.
TorresL., ArazoP., Blas PérezJ., AmadorM.P., LezcanoM.A., RevillaM.J., and García-MoyaJ.B.. 2000. Mycobacterium tuberculosis resistance in Zaragoza (1993–1997) and associated factors. [In Spanish]. Med. Clin., 115:605–609.
27.
BlanquerR., RodrigoT., CasalsM., Ruiz ManzanoJ., García-GarcíaJ.M., CalpeJ.L., ValenciaE., PascualT., MirI., JiménezM.A., CañasF., VidalR., PenasR.A., and CaylàJ.A.. 2015. Resistance to first-line antituberculosis drugs in Spain during 2010–2011. RETUBES study. [In Spanish]. Arch. Bronconeumol., 51:24–30.
28.
Caminal MonteroL., Trapiella MartínezL., Fernández Bernaldo De QuirósJ., and Telenti AsensioM.. 2002. Tuberculosis characteristics in a general hospital during 1993–1998. Resistance analysis and HIV coinfection. [In Spanish]. Enferm. Infecc. Microbiol. Clin., 20:68–73.
29.
PerdigãoJ., MacedoR., SilvaC., PintoC., FurtadoC., BrumL., and PortugalI.. 2010. Tuberculosis drug-resistance in Lisbon, Portugal: a 6-year overview. Clin. Microbiol. Infect., 17:1397–1402.
30.
FurtadoC., and BrumL.. 2003. Laboratory surveillance of drug resistance tuberculosis in Portugal in 2000–2001. Rev. Port Pneumol., 9:279–291.
31.
GomesC., MendesB., PinaJ., and Marques GomesM.J.. 1998. Antibacterial resistance. [In Spanish]. Rev. Port Pneumol., 4:155–163.
32.
RuizP., GutiérrezJ.B., Rodríguez-CanoF., ZeroloF.J., and CasalM.. 2004. Activity of Rifampin against Mycobacterium tuberculosis in a Reference Center. Microb. Drug Resist., 10:239–242.
33.
RuizP, Rodríguez-CanoF., ZeroloF.J., and CasalM.. 2003. Current interest of isoniazid in the chemotherapy of tuberculosis in the light of its in vitro activity. Microb. Drug Resist. Fall., 9:313–316.
34.
RuizP, Rodríguez-CanoF., ZeroloF.J., and CasalM.. 2002. Investigation of the in vitro activity of streptomycin against Mycobacterium tuberculosis. Microb. Drug Resist., 8:147–149.
35.
GilpinC, KorobitsynA., and WeyerK.. 2016. Current tools available for the diagnosis of drug-resistant tuberculosis. Ther. Adv. Infect. Dis., 3:145–151.
